retatrutide type 2 diabetes trial results 2024 2025 Effects of on body composition in people with diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised Lilly's triple agonist delivers up

Critical Care Medicine 32 (3): 848-51

In the context of obesity treatment, glucagon receptor activation promotes thermogenesis (heat production) and enhanced fat oxidation

A range of GLP-1RAs has been formulated, each exhibiting distinct pharmacokinetic characteristics

Promotes a feeling of control over the situation

Background There were two GLP-1 products that were initially approved and marketed for treating type-2 diabetes but, because they also had successful weight loss results, the manufacturers each got FDA approval to sell the products under two separate indications, one indicated for type 2 diabetes and one for weight loss, each with its own brand name and National Drug Code (NDC) identification number